Last reviewed · How we verify
Lidocaine-epinephrine added gadoterate meglumine
Lidocaine-epinephrine added gadoterate meglumine is a Small molecule drug developed by Thomas F. Bendtsen. It is currently in Phase 2 development.
At a glance
| Generic name | Lidocaine-epinephrine added gadoterate meglumine |
|---|---|
| Sponsor | Thomas F. Bendtsen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Shamrock - Ultrasound/MR Image Fusion Guided Lumbar Plexus Block (PHASE2)
- Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine-epinephrine added gadoterate meglumine CI brief — competitive landscape report
- Lidocaine-epinephrine added gadoterate meglumine updates RSS · CI watch RSS
- Thomas F. Bendtsen portfolio CI
Frequently asked questions about Lidocaine-epinephrine added gadoterate meglumine
What is Lidocaine-epinephrine added gadoterate meglumine?
Lidocaine-epinephrine added gadoterate meglumine is a Small molecule drug developed by Thomas F. Bendtsen.
Who makes Lidocaine-epinephrine added gadoterate meglumine?
Lidocaine-epinephrine added gadoterate meglumine is developed by Thomas F. Bendtsen (see full Thomas F. Bendtsen pipeline at /company/thomas-f-bendtsen).
What development phase is Lidocaine-epinephrine added gadoterate meglumine in?
Lidocaine-epinephrine added gadoterate meglumine is in Phase 2.